Guillaume defended his PhD thesis about the natural transducing ability of telomerase in 2009 (mentor Pr. Michelle Hadchouel, Paris-Diderot University), and performed a 2-year post-doctoral training working on lentiviral vectors at the Institute of Emerging Diseases and Innovative Therapies(IMETI) directed by Dr. Philippe Leboulch, at the Commissariat à l'Energie Atomique (CEA). In 2011, he joined the UMR-1007 at the Paris-Descartes University in the group of Dr. Sophie Bombard, where he has mainly worked on telomerase-related projects funded by the SATT IDFINNOV, in collaboration with the Curie Institute. In 2016, he joined the laboratory directed by Pr. Nicolas Leulliot at the Faculty of Pharmacy of Paris-Descartes University to set the production of telomerase in fermentor, and founded Telomium.
Director of the CMO Eurogentec (1989-1988), Jean joined GSK in 1999 and became Vice-President Head of New Products Development (2012-2014) at GLAXOSMITHKLINE VACCINES. Since 2016, he now works mainly as a consultant for biotech companies. He met Telomium in 2018 and agreed to advise us in the technical development of our product.
Globe-trotter and Business developer for Industry & Academia Partnerships. Kevin was CEO of French Biobeach, a platform promoting partnering between California and Europe. Kevin was also scientific collaborator at the Salk Institute and the Scripps Research Institute (La Jolla). He obtained a bachelor in innovation management (Global Innovation Management Institute). After a master in Oncology (ENS Cachan), he got a PhD (Cochin hospital) and a post-doc in Tony Hunter’s lab (Salk Institute).
- Professor François-Clément Bidard.